Name: Acyclovir (Aciclovir)
Brand: Selleck Chemicals
SKU: S1807
Rating: 5 (20 reviews)

Aller à

Contrôle Qualité (Quality Control)

Lot : Pureté : 99.93%

99.93

Cibles apparentées	Integrase Bacterial Antibiotics Anti-infection Fungal COVID-19 Parasite Reverse Transcriptase HIV HCV Protease
Autre Antiviral Inhibiteurs	Moroxydine HCl Aloperine GS-441524 Oleanolic Acid Harringtonine NGI-1 U-18666A LL-37 acetate Aloin B Lanatoside C

Culture cellulaire, traitement et concentration de travail
(Cell Culture, Treatment & Working Concentration)

Lignées cellulaires	Type d'essai	Temps d'incubation	Description de l'activité
BSC-1 cells	Function assay		Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells, IC50=2.6 μM
P3HR-1 cells	Function assay		Effective concentration for the inhibition of Epstein-Barr virus EBV-DNA synthesis in human lymphoblastoid P3HR-1 cells, EC50=6.75 μM
HFF cells	Function assay		Concentration for HSV-1 plaque reduction (VPR) by 50% in HFF cells, EC50=1.1 μM
HFF cells	Function assay		Inhibitory concentration required to reduce HSV-1 induced cytopathogenic effect (CPE) by 50 % in HFF cells, EC50=2.22 μM
human embryonic lung cells	Function assay		Antiviral activity was measured as effective concentration required to reduce Varicella Zoster virus (OKA)-induced plaque formation in human embryonic lung cells, EC50=1.1 μM
HEL cells	Function assay		Compound was tested for anti-viral activity against HSV-1(G) in HEL cells, EC50=1.3 μM
HEL cell	Function assay		Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in OKA strain HEL cell lines, EC50=4.53 μM
HSV-2 MS Vero cells	Function assay		Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell monolayers of HSV-2 MS Vero cells by 50%, EC50=6.2 μM
HSV-1 E-377 Vero cells	Function assay		Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50%, EC50=4.4 μM
HSV-1 KOS Vero cells	Function assay		Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50%, EC50=2.2 μM
HeLa cell	Function assay		Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (G) in HeLa cell culture, IC50=0.19 μM
HEp-2 cells	Function assay		Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (K979) in HEp-2 cells
HeLa cells	Function assay		Inhibition of HSV-1 DNA synthesis in virus-infected HeLa cells, IC50=1.9 μM
human HFF cells	Function assay		Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells, EC50=0.04 μM
human HFF cells	Function assay		Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells, EC50=0.09 μM
MRC-5 cells	Function assay		Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 2 (HSV-2) in MRC-5 cells, IC50=2.5 μM
human lung fibroblasts (MRC-5)	Function assay		Compound was tested for antiviral activity against Herpes Simplex virus Type-1(18189) in human lung fibroblasts (MRC-5)
Raji cells	Function assay		Inhibitory concentration of the drug against the antigen production against P3HR-1 strain of epstein barr virus-2 (EBV) in Raji cells, EC50=2.9 μM
Vero cells	Function assay		Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells, IC50=1.7 μM
BSC-1 cells	Function assay		Effective concentration required to inhibit herpes simplex virus 1 in BSC-1 cells in ELISA, EC50=1.5 μM
HFF cells	Function assay		Effective concentration required to inhibit varicella zoster virus replication in HFF cells, EC50=1.6 μM
HFF cells	Function assay		Effective concentration required to inhibit herpes simplex virus 1 in HFF cells in cytopathic effect (CPE) assay, EC50=0.9 μM
Daudi cells	Function assay		Inhibition of EBV replication in Daudi cells by viral capsid antigen-ELISA, EC50=0.33 μM
african green monkey Vero cells	Function assay	48 h	Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay, EC50=1.87 μM
WI-38 cell	Function assay		Anti viral activity against VZV(pplla strain) in WI-38 cell monolayers, ID50=4 μM
HEL cells	Function assay	4 days	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days, EC50=0.2 μM
HEL cells	Function assay		Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.14 μM
African green monkey Vero 76 cells	Cytotoxicity assay	48-96 h	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining, CC50=13 μM
Cliquez pour voir plus de données expérimentales sur la lignée cellulaire

Informations chimiques, stockage et stabilité (Chemical Information, Storage & Stability)

Poids moléculaire	225.2	Formule	C₈H₁₁N₅O₃	Stockage (À compter de la date de réception)	3 ans-20°Cpoudre
N° CAS	59277-89-3	Télécharger le SDF		Stockage des solutions mères	1 an-80°Cen solvant 1 mois-20°Cen solvant
Synonymes	Acycloguanosine, ACV, NSC 645011,BW 248U			Smiles	C1=NC2=C(N1COCCO)N=C(NC2=O)N

Solubilité (Solubility)

In vitro
Lot:

DMSO : 45 mg/mL (199.82 mM)
(Le DMSO contaminé par l'humidité peut réduire la solubilité. Utiliser du DMSO frais et anhydre.)

Water : Insoluble

Ethanol : Insoluble

Calculateur de molarité

Masse	Concentration	Volume	Poids moléculaire
=	×	×

Calculateur de dilution Calculateur de poids moléculaire

In vivo Lot:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validé par les laboratoires Selleck. Si vous avez besoin d'ajustements à cette formulation, contactez notre équipe commerciale pour des tests personnalisés.	2.500mg/ml (11.10mM)	Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validé par les laboratoires Selleck. Si vous avez besoin d'ajustements à cette formulation, contactez notre équipe commerciale pour des tests personnalisés.	2.500mg/ml (11.10mM)	Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

Calculateur de formulation in vivo (Solution claire)

Étape 1 : Saisir les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant l'expérience)

Dosage : mg/kg Poids moyen des animaux : g Volume de dosage par animal :μL Nombre d'animaux :

Étape 2 : Saisir la formulation in vivo (Ceci est seulement le calculateur, pas la formulation. Veuillez nous contacter d'abord s'il n'y a pas de formulation in vivo dans la section Solubilité.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Résultats du calcul :

Concentration de travail : mg/ml;

Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter d'abord si la concentration dépasse la solubilité du DMSO du lot de médicament. )

Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouterμL PEG300, mélanger et clarifier, puis ajouterμL Tween 80, mélanger et clarifier, puis ajouter μL ddH₂O, mélanger et clarifier.

Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouter μL Huile de maïs, mélanger et clarifier.

Note : 1. Veuillez vous assurer que le liquide est clair avant d'ajouter le solvant suivant.
2. Assurez-vous d'ajouter le(s) solvant(s) dans l'ordre. Vous devez vous assurer que la solution obtenue, lors de l'ajout précédent, est une solution claire avant de procéder à l'ajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie chaud peuvent être utilisées pour faciliter la dissolution.

Mécanisme d'action (Mechanism of Action)

Targets/IC₅₀/Ki	HSV
In vitro	In a plaque-reduction assay in Vero cells, the Acyclovir (Aciclovir) sensitivity of herpes simplex virus isolates is determined. IC50 Values are consistently 2-3 fold lower in B2 compared with the H strain of Vero cells. HSV Type 2 strains are 2-10-fold less sensitive than Type 1 strains.
In vivo	low-dose oral acyclovir (aciclovir) may be effective in the prevention of HSV infection during OKT3 treatment of seropositive patients. Continuation of this compound for two to four weeks following the conclusion of OKT3 therapy may prevent occurrence of delayed infections.
Références	[1] https://pubmed.ncbi.nlm.nih.gov/3913459/ [2] https://pubmed.ncbi.nlm.nih.gov/3025149/ [3] https://pubmed.ncbi.nlm.nih.gov/2652575/

Informations sur l'essai clinique (Clinical Trial Information)

(données du https://clinicaltrials.gov, mis à jour le 2024-05-22)

Numéro NCT	Recrutement	Conditions	Promoteur/Collaborateurs	Date de début	Phases
NCT06228430	Not yet recruiting	Healthy Volunteer	International Bio service	February 12 2024	Phase 1
NCT05589688	Not yet recruiting	Obesity	University Hospital Toulouse	January 2024	Phase 1
NCT06058858	Not yet recruiting	Cytomegalovirus Infections\|Acute Leukemia\|B Cell Lymphoma	Assistance Publique - Hôpitaux de Paris	October 1 2023	--
NCT05468619	Recruiting	Herpes Simplex	National Institute of Allergy and Infectious Diseases (NIAID)	September 23 2022	Phase 1

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Acyclovir (Aciclovir) Antiviral Chimique

Poids moléculaire: 225.2

Contrôle Qualité (Quality Control)

Culture cellulaire, traitement et concentration de travail
(Cell Culture, Treatment & Working Concentration)

Informations chimiques, stockage et stabilité (Chemical Information, Storage & Stability)

Solubilité (Solubility)

Calculateur de molarité

Calculateur de formulation in vivo (Solution claire)

Mécanisme d'action (Mechanism of Action)

Informations sur l'essai clinique (Clinical Trial Information)

Acyclovir (Aciclovir) Antiviral Chimique

Poids moléculaire: 225.2

Contrôle Qualité (Quality Control)

Culture cellulaire, traitement et concentration de travail (Cell Culture, Treatment & Working Concentration)

Informations chimiques, stockage et stabilité (Chemical Information, Storage & Stability)

Solubilité (Solubility)

Calculateur de molarité

Calculateur de formulation in vivo (Solution claire)

Mécanisme d'action (Mechanism of Action)

Informations sur l'essai clinique (Clinical Trial Information)

Culture cellulaire, traitement et concentration de travail
(Cell Culture, Treatment & Working Concentration)